RAM PHARMA

Magnacef®

Cefixime

Description:

Magnacef (Cefixime) is a semi-synthetic third generation cephalosporin which has a bactericidal action against most strains of organisms including penicillinase producing strains. **Magnacef** has an average peak plasma concentrations occurring within 4 hrs after oral administration with a half-life of 3 - 4 hrs.

Age	Dose / Day Teaspoonful	Dose / Day ML
6 months - 1 year	$^1/_2$ - $^3/_4$	2.5 - 4
2 - 4 year	1	5
5 - 11 year	1, $^1/_4$ - 2	6 - 10

Indications: Magnacef is indicated for the treatmenmt of:

- Upper respiratory tract infections: Otitis media, pharyngitis and tonsilitis.
- Lower respiratory tract infections: Acute bronchitis and acute exacerbation of chronic bronchitis.
- Uro-genital infections and sexually transmitted diseases such as gonorrhoea.

Dosage and Administration: Magnacef may be taken regardless to meals. Administration with food may decrease the rate of absorption. As for all antibiotics **Magnacef** should be taken for full course treatment.

Adults and Children over 12 years (50 kg body weight): 200 mg every 12 hrs or 400 mg once daily.

Children 6 months of age - 12 years: 4 mg / kg of body weight every 12 hrs or 8 mg / kg body weight once daily.

Contraindications:

- Hypersensitivity to cephalosporin antibiotics.

Precautions:

- In patients with renal impairment: Dosage must be adjusted according to creatinine clearance.
- Should be prescribed with caution to individuals with a history of gastrointestinal diseases particularly colitis.
- Prolonged use of anti-infective may result in overgrowth of non-susceptible organisms.
- Reproduction studies have been performed in mice and rats at doses up to 400 times the human dose and have revealed no evidence of harm to the fetus due to cefixime.
- There are no adequate and well-controlled studies, Therefore, this drug should be used during pregnancy only if clearly needed (pregnancy; category B). It is not known whether cefixime is excreted in human milk; however problems in humans have not been documented to date.

Adverse Effects:

- Gastrointestinal: Diarrhea, abdominal pain nausea and vomiting
- Hypersensitivity: skin rash and urtic aria.
- Few patients show transient elevations in SGOT, SGPT, BUN, creatinine and alkaline phosphatase.

Presentation:

Magnacef -200 mg Capsules: Each capsule contains Cefixime Trihydrate (USP)equivalent to 200mg Cefixime. Blister packs of 8 capsules.

Magnacef -400 mg Capsules: Each capsule contains Cefixime Trihydrate (USP)equivalent to 400mg Cefixime. Blister packs of 5,6 capsules.

Magnacef for Oral Suspension: Each 5 ml of reconstituted suspension contains Cefixime Trihydrate (USP) equivalent to 100 mg Cefixime. Bottles of 30 and 60 ml suspension.

Hospital packs of different sizes are available.

Some presentations may not be available in certain countries.

This is a Medicament :

- Keep all medicaments away from children.
- A medicament is a product that affects your health, and its consumption. contrary to instructions is dangerous.
- Strictly follow the doctor's prescription, the method of use and the instructions of the pharmacist who dispensed the medicament.
- The doctor and the pharmacist are experts in medicine, its benefits and risks.
- Do not interrupt the treatment before consulting your doctor.
- Do not repeat the same prescription without consulting your doctor.

COUNCIL OF ARAB HEALTH MINISTERS
UNION OF ARAB PHARMACISTS

RAM PHARMA ceutical Industries Co.Ltd,
P.O BOX 211 Industrial Estate Sahab- 11512 Jordan.

Mag 8/2001